Literature DB >> 16159079

Reversal of locked-in syndrome with anticoagulation, induced hypertension, and intravenous t-PA.

Nazli Janjua1, Katja E Wartenberg, Philip M Meyers, Stephan A Mayer.   

Abstract

INTRODUCTION: Widespread use of intravenous tissue plasminogen activator (t-PA) for acute ischemic stroke is limited by multiple contraindications to its use. CASE REPORT: This article describes a patient with stuttering symptoms of pontine ischemia caused by vertebrobasilar dissection who suddenly deteriorated into a locked-in state 32 hours after symptom onset. The quadriparesis was successfully reversed within 3 hours of onset with the combination of pharmacologically induced hypertension, anticoagulation, and intravenous t-PA. DISCUSSION: Even in the face of numerous contraindications (including hypertension, anticoagulation, and treatment beyond 3 hours of symptom onset), intravenous t-PA can be used successfully in carefully selected cases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16159079     DOI: 10.1385/NCC:2:3:296

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN: 1541-6933            Impact factor:   3.210


  17 in total

1.  Thrombolysis in patients with acute stroke caused by cervical artery dissection: analysis of 9 patients and review of the literature.

Authors:  Marcel Arnold; Krassen Nedeltchev; Matthias Sturzenegger; Gerhard Schroth; Thomas J Loher; Frank Stepper; Luca Remonda; Claudio Bassetti; Heinrich P Mattle
Journal:  Arch Neurol       Date:  2002-04

2.  Successful thrombolytic treatment of intracranial carotid occlusion due to dissection.

Authors:  S Leistner; A Hartmann; P Marx; H C Koennecke
Journal:  Eur Neurol       Date:  2001       Impact factor: 1.710

3.  Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.

Authors:  W M Clark; S Wissman; G W Albers; J H Jhamandas; K P Madden; S Hamilton
Journal:  JAMA       Date:  1999-12-01       Impact factor: 56.272

4.  Intravenous tPA in acute ischemic stroke related to internal carotid artery dissection.

Authors:  L Derex; N Nighoghossian; F Turjman; M Hermier; J Honnorat; P Neuschwander; J C Froment; P Trouillas
Journal:  Neurology       Date:  2000-06-13       Impact factor: 9.910

5.  Stroke following internal carotid artery occlusion - a contra-indication for intravenous thrombolysis?

Authors:  J Rudolf; M Neveling; M Grond; S Schmulling; C Stenzel; W D Heiss
Journal:  Eur J Neurol       Date:  1999-01       Impact factor: 6.089

6.  Thrombolytic therapy of acute basilar artery occlusion. Variables affecting recanalization and outcome.

Authors:  T Brandt; R von Kummer; M Müller-Küppers; W Hacke
Journal:  Stroke       Date:  1996-05       Impact factor: 7.914

7.  Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial.

Authors:  C A Lewandowski; M Frankel; T A Tomsick; J Broderick; J Frey; W Clark; S Starkman; J Grotta; J Spilker; J Khoury; T Brott
Journal:  Stroke       Date:  1999-12       Impact factor: 7.914

8.  Tissue plasminogen activator in a vertebral artery dissection.

Authors:  A P Gasecki; C Graffagnino; V Hachinski
Journal:  Can J Neurol Sci       Date:  1997-05       Impact factor: 2.104

9.  A pilot study of drug-induced hypertension for treatment of acute stroke.

Authors:  G Rordorf; W J Koroshetz; M A Ezzeddine; A Z Segal; F S Buonanno
Journal:  Neurology       Date:  2001-05-08       Impact factor: 9.910

10.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

View more
  1 in total

1.  Locked-in syndrome in Sweden, an explorative study of persons who underwent rehabilitation: a cohort study.

Authors:  Kajsa Svernling; Marie Törnbom; Åsa Nordin; Katharina S Sunnerhagen
Journal:  BMJ Open       Date:  2019-04-20       Impact factor: 2.692

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.